50 results on '"Derrett-Smith, Emma"'
Search Results
2. Skin biopsy analysis of concurrent keloidal morphoea and systemic sclerosis confirms overlapping pathogenic pathways
3. Management of systemic sclerosis: British Society for Rheumatology guideline scope
4. Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study
5. A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis
6. P229 Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis
7. The value of ultrasound-defined tenosynovitis and synovitis in the prediction of persistent arthritis
8. Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF-β/Wnt3a Is Mediated by GLI2 Upregulation
9. Autoantibodies in autoimmune rheumatic disease
10. The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis
11. Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis
12. Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis
13. O18 Integrated molecular analysis of systemic sclerosis skin and blood shows significant differences between major autoantibody subgroups
14. P154 High-density proteomic analysis of skin blister fluid and plasma in systemic sclerosis identifies local and systemic differences for key proteins
15. Advances in Vascular Medicine
16. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
17. P152 Skin score trajectory associates with survival and pulmonary outcome in diffuse cutaneous systemic sclerosis
18. P151 Forced vital capacity in patients with systemic sclerosis associated pulmonary fibrosis: predictors of meaningful decline
19. P154 Stage and subset specific profiles of fibrogenesis highlighted through analysis of serum markers across the scleroderma spectrum
20. Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis
21. Prospects for Stratified and Precision Medicine in Systemic Sclerosis Treatment
22. O04 In vivo assessment of prevention of lung fibrosis using the pan-PPAR agonist lanifibranor in the TbRIIDk-fib mouse model of systemic sclerosis
23. E074 Developing a molecular classifier for scleroderma spectrum disorders to augment clinical categorisation
24. E079 Whole genome expression analysis from paired samples of keloidal morphea and systemic sclerosis skin identifies key scleroderma candidate genes
25. 020 Evidence for altered peroxisome proliferator activated receptor (PPAR) pathway activity in a transgenic mouse model of scleroderma (TbRIIDk-fib): analysis of mouse skin, lung and explanted cells
26. What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study
27. Transforming Growth Factor β Activation Primes Canonical Wnt Signaling Through Down-Regulation of Axin-2
28. O13 A simple classification of systemic sclerosis using subset and autoantibodies can discriminate well between distinct outcome groups
29. Autoantibodies in autoimmune rheumatic disease
30. Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor
31. Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature
32. DERMATOLOGY033. MULTITISSUE GENE EXPRESSION PATHWAY ANALYSIS OF MERGING THERAPEUTICS IN A TRANSFORMING GROWTH FACTOR BETA–DEPENDENT MOUSE MODEL OF SYSTEMIC SCLEROSIS
33. 057. LIMITED CUTANEOUS SYSTEMIC SCLEROSIS SKIN DEMONSTRATES MOLECULAR SUBSETS THAT INCLUDE A CARDIOVASCULAR DEVELOPMENT GENE EXPRESSION SIGNATURE
34. O15. DYNAMIC PREDICTION OF PULMONARY HYPERTENSION DEVELOPMENT IN SYSTEMIC SCLEROSIS PATIENTS USING LANDMARK ANALYSIS
35. Resolution of paraneoplastic PM/Scl-positive systemic sclerosis after curative resection of a pancreatic tumour
36. Impaired Bone Morphogenetic Protein Receptor II Signaling in a Transforming Growth Factor-β–Dependent Mouse Model of Pulmonary Hypertension and in Systemic Sclerosis
37. 312. Perturbed Response to Experimental Renal Injury in a Mouse Model of Systemic Sclerosis
38. O56. Microarray Transcriptional Profiling of Limited Cutaneous Systemic Sclerosis Identifies a Vascular Gene Expression Signature
39. Systemic sclerosis: clinical features and management
40. Pulmonary endothelial injury in the context of perturbed transforming growth factor β signalling as a unique model of pulmonary hypertension in scleroderma
41. Endothelial Injury in a Transforming Growth Factor β–Dependent Mouse Model of Scleroderma Induces Pulmonary Arterial Hypertension
42. Revisiting ANCA-associated vasculitis in systemic sclerosis: clinical, serological and immunogenetic factors
43. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
44. Correspondence
45. An Essential Role for Resident Fibroblasts in Experimental Lung Fibrosis Is Defined by Lineage-Specific Deletion of High-Affinity Type II Transforming Growth Factor β Receptor
46. Systemic sclerosis: clinical features and management
47. Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma
48. Animal models of scleroderma: lessons from transgenic and knockout mice
49. B-cell-targeted therapies: promising new treatments for systemic lupus erythematosus
50. Therapeutic transforming growth factor-β blockade in systemic sclerosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.